Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. - Wikidata - awgldk - TriplyDB

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

http://www.wikidata.org/entity/Q37097096

about

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy Management of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Venetoclax for the treatment of patients with chronic lymphocytic leukemia.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Myelofibrosis: an update on drug therapy in 2016.Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.Current Treatment of Chronic Lymphocytic Leukemia.Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Prostatic-Like Syndrome in a Woman with Chronic Lymphocytic Leukemia: Sequential Kinase Inhibitor Therapy.Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.Recent therapeutic advances in chronic lymphocytic leukemia.The PI3K Pathway in Human Disease.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.Venetoclax for the treatment of chronic lymphocytic leukemia.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.

P2860

Q28075504-6D0B81DC-0162-4BE1-84E5-A129F3E62748 Q29248893-A988C167-41D3-4F16-8C7C-8680926D2811 Q30243914-A5ABFD7D-BD6C-4E74-B89C-6DE6F37B5051 Q30243968-397591CA-C147-413F-8AFE-289A83BDDAC5 Q33439333-5B4F78D3-FAFD-4D72-9980-489B6C9DA48A Q37321917-D662A899-08E6-464A-821A-97D174A1A169 Q37605306-8F8E6637-DE78-4328-ADE5-036BB24FD544 Q37725415-70348D35-D9D6-434B-8BCD-00CB1FB0DF59 Q38654101-BB7B5508-A8F9-4731-9133-00D305E354D8 Q38673045-BC792222-65AC-4400-83F1-C547D3863AFE Q38684435-59E3897E-6A57-4F1E-89FE-5BDF7EA43E90 Q38685358-C69AFE57-F314-4CA4-906F-F7701CA7734B Q38691282-2BEFF1DF-9D2E-4E05-BFE1-5511CA746AC3 Q38818283-AC6789A3-2AAA-4F69-8D6B-70717D6EB477 Q38939419-191934E9-55E0-489D-81F2-E63B724612EC Q38982682-E396DC8A-151A-4EBA-9F27-FFBC8820886E Q38984735-ED63FE71-FFA5-4583-841C-BFABD786E65E Q38989215-C66F5D59-0437-4B7D-8B1A-98D2FE98A40B Q39098904-5D4CD758-7B4E-4596-988E-13AB38227ABE Q39129372-D24B8562-DA30-4D9E-A526-67E7C43DD9AE Q39145934-98378728-CDB4-47E9-96C8-ECD230A0F918 Q39154057-7D58F6FE-A14B-4378-A495-6FFA91DCEC16 Q39169789-3EB7DACF-99B4-4CC1-A87E-826125892EB1 Q39200835-79922F99-055F-4F21-8A63-21E347E3F952 Q39226787-AA02001B-69D1-4EB6-ACE1-316CA46AE549 Q41022820-0CBCAE21-E500-465D-B6C7-F3813D22EEDD Q41471269-243507D3-A48D-4FFC-B8FD-141F3E412860 Q41994564-1F08180C-33A7-4FA8-839A-A0E35F14D77A Q42368314-CF4E387B-8659-409D-AC53-AF17641B3DB3 Q42372842-296B1A68-97A2-47BD-A441-28926CBA36F3 Q46074725-19621A5B-C4F2-45D6-A48C-CC070DE7571B Q46318389-AC35CFFB-5B37-4056-B6E6-9B507501EAE2 Q46546002-2B79D683-8015-4E2C-99DD-92425E2EF46C Q47300115-5B939CA7-3B63-409A-B370-2535A602B4FD Q47796704-A8F1A5F7-DE10-499B-9368-9D3C91A781C6 Q47875923-75D07319-617C-4733-8A4F-372870BFC645 Q47932240-01917599-E58F-4BA5-9841-7A163400B5F8 Q48304637-5D8121C0-9A49-476A-AB87-437EB1F052DD Q49692075-10FDBC6B-335F-496F-B857-D79309A2518C Q49887083-4D71C6DC-465B-4AE0-B7AE-5E2E862FF674

P2860

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

http://www.wikidata.org/entity/Q37097096

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Idelalisib given front-line fo ...... mmune-mediated hepatotoxicity.

@en

Idelalisib given front-line fo ...... mmune-mediated hepatotoxicity.

@nl

type

label

Idelalisib given front-line fo ...... mmune-mediated hepatotoxicity.

@en

Idelalisib given front-line fo ...... mmune-mediated hepatotoxicity.

@nl

prefLabel

Idelalisib given front-line fo ...... mmune-mediated hepatotoxicity.

@en

Idelalisib given front-line fo ...... mmune-mediated hepatotoxicity.

@nl

P1433

Q37097096-5A8D011C-4D35-4BAE-98C1-31E35167849D

P1476

Q37097096-16AB1820-E643-4E91-A296-6F3B6DF26CCD

P2093

Q37097096-0F3CF72B-ECD3-4DAC-9CA9-1239CC38DB95

Q37097096-12707F0B-E5CC-448E-AEB1-A0A06136CD62

Q37097096-19229E51-8ED8-420C-87B6-E95915992F28

Q37097096-2A568D4A-0DBA-44D9-92C4-AB1FADE632CC

Q37097096-3EF6727B-2453-4201-B3AF-42645DCBFE5E

Q37097096-4DB51DA7-1C32-404C-AEA8-C9F79AC30801

Q37097096-85350831-9296-4D47-87A2-573E9F5797F6

Q37097096-8651313E-450D-46E5-AC93-14C2B0AADF6C

Q37097096-99EDF6BE-529D-4F9D-B8B5-1367C12DB556

Q37097096-A47DEA45-B1C6-449B-9E1F-B080F83AF53F

P2860

Q37097096-04E1167E-48EC-422D-8692-EAB3F8BD3CB8

Q37097096-120FD621-3DFB-49A0-B713-4E0E1CD2501D

Q37097096-18E6910D-B2B5-4FBB-BC0D-CD19BBDBFB85

Q37097096-1E74D95C-5CFF-4BE7-A551-504DE0AC7E38

Q37097096-2C39EE1C-6080-438B-9701-CC8397F2E58E

Q37097096-3044FEF9-4C8C-46DC-B3B0-848DAAF7DC28

Q37097096-38719226-66F5-4242-BCE8-92A0F5CDCB6A

Q37097096-3A1037F4-4EA9-4BAB-8517-7C0A6E520B1A

Q37097096-3E772345-A61D-44DC-97A6-EE98F19EC699

Q37097096-41271036-0EF7-44AB-A9B9-8D79EFB0986A

P304

Q37097096-F1204B91-493D-42D2-BE62-BC48291C8D08

P31

Q37097096-9197770A-2B20-419D-9244-FBE0897175D7

P356

Q37097096-DFF205FD-7DCD-43E2-B485-A63954EF2DD1

P407

Q37097096-DFD41066-4359-467E-B8E8-937EE3222105

P433

Q37097096-152FB3CE-31A1-4864-895E-9CEFDD40B29A

P478

Q37097096-98314D76-07D8-4F3E-8762-3C0028FA8BC5

P50

Q37097096-24D56041-CC38-4BD0-A824-D8BBC8AA81BC

Q37097096-3A274592-741D-4AF0-92E3-F380B1CADF9D

Q37097096-6F99E7B5-C43F-474F-A7C8-61379C18015B

Q37097096-7C327854-74B9-4736-AFFE-CB09D33B0EAB

Q37097096-85F3A2C1-4EE9-4676-8DCD-77149E6C47C8

Q37097096-DC3DE359-E5F3-425B-B4D3-45ECC2282F1E

P577

Q37097096-8D91FC9F-9FF7-4B35-A9E3-0213EC299B6C

P698

Q37097096-7920F359-FC66-491B-94EC-B6B381CE4B8B

P921

Q37097096-BA4FA199-F45C-4855-A20E-8DFDB28601C3

Q37097096-CEA93283-A244-4C40-9D22-B61BC818F211

Q37097096-F4FD6843-1521-42F0-BC18-0F1F108A8B52

P932

Q37097096-F7F46DD3-FCC1-4BAA-8999-73FE1010F4D1

P356

BLOOD-2016-03-707133

P1433

P1476

Idelalisib given front-line fo ...... immune-mediated hepatotoxicity

@en

P2093

Arnold S Freedman

http://www.w3.org/2001/XMLSchema#string

Caron A Jacobson

http://www.w3.org/2001/XMLSchema#string

David C Fisher

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

Jeremy S Abramson

http://www.w3.org/2001/XMLSchema#string

John Hanna

http://www.w3.org/2001/XMLSchema#string

Jon E Arnason

http://www.w3.org/2001/XMLSchema#string

Laura Rassenti

http://www.w3.org/2001/XMLSchema#string

Matthew S Davids

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

IMGT, the international ImMunoGeneTics information system

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Mechanisms of drug-induced liver injury.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells.

P304

195-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-03-707133

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Morgan

Benjamin L Lampson

P577

2016-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27247136

http://www.w3.org/2001/XMLSchema#string

P921

P932

4946200

http://www.w3.org/2001/XMLSchema#string